Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.3.5 (5'-nucleotidase)
 3,167 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effect of changes in dietary sodium intake and of DOC hypertension on plasma atrial natriuretic peptide (PANP), and affinity (Kd) and number (Bmax) of vascular atrial natriuretic peptide binding sites was studied in the rat. There was no difference in PANP between rats on a high or low sodium intake [33.2 +/- 13.9 versus 30.7 +/- 17.3 (s.d.) fmol/ml], Kd [21.1 +/- 2.7 versus 19.7 +/- 4.5 (s.d.) pmol/l] or Bmax [14.8 +/- 1.6 versus 12.6 +/- 1.8 (s.d.) fmol/mg], respectively. In DOC hypertensive rats, PANP was increased compared with control animals [66.1 +/- 32.4 versus 26.4 +/- 9.9 (s.d.) fmol/ml, P less than 0.05] and there was apparent receptor down-regulation [Bmax 7.7 +/- 1.6 versus 19.7 +/- 3.5 (s.d.) fmol/mg, P less than 0.05] with no change in affinity [Kd 15.6 +/- 3.9 versus 18.3 +/- 3.2 (s.d.) pmol/l]. Down-regulation was confirmed when the membrane-bound enzyme 5'-nucleotidase, rather than protein, was used as an index of receptor number. These results suggest that in the rat, atrial natriuretic peptide (ANP) may be important in regulating cardiovascular homeostasis only following non-physiological alterations in sodium and volume status.
 ...
PMID:Rat atrial natriuretic peptide vascular receptor: effect of alterations in sodium balance and of DOC hypertension. 282 98

Adenosine has been shown to exert direct antihypertrophic effects on the heart, and plasma adenosine levels have been shown to be elevated in patients with heart failure. It has therefore been proposed that endogenously synthesized adenosine may function as a cardiac antihypertrophic factor. The present study was aimed to determine whether the adenosine system is altered in a potential adaptive manner following phenylephrine-induced hypertrophy in cultured neonatal rat ventricular myocytes. Phenylephrine produced significant hypertrophy as determined by cell size and atrial natriuretic peptide gene expression, which was accompanied by significantly increased gene and protein expression of adenosine A(1), A(2a), and A(3) receptors. These effects and the hypertrophic response were prevented by the alpha(1)-adrenoceptor antagonist prazosin as well as pharmacological agonists for all adenosine receptor subtypes. The upregulation of adenosine receptors by phenylephrine was also abrogated by adenosine 5'-(alpha,beta-methylene)diphosphate, an inhibitor of ectosolic 5'-nucleotidase. Moreover, phenylephrine significantly increased production of adenosine from myocytes in the presence of a nucleoside transport and adenosine deaminase inhibitor, the combination of which abrogated the hypertrophic effect of phenylephrine. The latter effect was reversed by adenosine receptor antagonists. Phenylephrine also produced a significant upregulation in expression levels of equilibrative nucleoside transporter 1 although expression levels of equilibrative nucleoside transporter 2 were unaffected. Taken together, our results suggest an adaptive upregulation of the adenosine system to phenylephrine-induced cardiomyocyte hypertrophy that serves to limit the hypertrophic effect of alpha(1-)adrenoceptor activation.
 ...
PMID:Compensatory upregulation of the adenosine system following phenylephrine-induced hypertrophy in cultured rat ventricular myocytes. 1996 59